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Abstract
Preeclampsia is an important cause of maternal and perinatal morbidity and mortality. Previous studies have tested calcium
supplementation and aspirin separately to reduce the incidence of preeclampsia but not the effects of combined
supplementation. The objective of this study was to investigate the effectiveness of aspirin combined with calcium
supplementation to prevent preeclampsia in women with chronic hypertension. A double-blind, placebo-controlled randomized
clinical trial was carried out at the antenatal clinic of a large university hospital in Sa˜o Paulo, SP, Brazil. A total of 49 women
with chronic hypertension and abnormal uterine artery Doppler at 20-27 weeks gestation were randomly assigned to receive
placebo (N = 26) or 100 mg aspirin plus 2 g calcium (N = 23) daily until delivery. The main outcome of this pilot study was
development of superimposed preeclampsia. Secondary outcomes were fetal growth restriction and preterm birth. The rate of
superimposed preeclampsia was 28.6% lower among women receiving aspirin plus calcium than in the placebo group (52.2 vs
73.1%, respectively, P=0.112). The rate of fetal growth restriction was reduced by 80.8% in the supplemented group (25 vs
4.8% in the placebo vs supplemented groups, respectively; P=0.073). The rate of preterm birth was 33.3% in both groups. The
combined supplementation of aspirin and calcium starting at 20-27 weeks of gestation produced a nonsignificant decrease in
the incidence of superimposed preeclampsia and fetal growth restriction in hypertensive women with abnormal uterine artery
Doppler.
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Introduction
Hypertensive disorders in pregnancy are still the
leading cause of maternal mortality in developing nations.
According to the most recent World Health Organization
review, hypertensive disorders accounted for 25% of all
maternal deaths in Latin America and the Caribbean,
leading to 3800 deaths each year in the region (1).
Superimposed preeclampsia is a condition characterized
by increasing blood pressure and proteinuria after the
20th week of pregnancy in women with pre-existing
chronic hypertension (2). Superimposed preeclampsia
usually develops earlier than other hypertensive disorders
of pregnancy, tends to be more severe, and can lead to
fetal growth restriction, elective preterm delivery, and
increased risk for perinatal mortality. It can also lead to
severe adverse maternal outcomes, including hyperten-
sive encephalopathy, heart or kidney failure, placental
abruption, HELLP (hemolysis, elevated liver enzymes,
low platelets) syndrome, and maternal mortality (3-5). It is
estimated that approximately 14 to 78% of all women with
pre-existing chronic hypertension will develop super-
imposed preeclampsia during pregnancy; those with
abnormal uterine artery Doppler are at even higher risk
(4-11).
Second-trimester uterine artery Doppler ultrasound
has been used for over a decade to screen women at high
risk of preeclampsia. Increased impedance to flow in the
uterine arteries in unselected women during the second
trimester of pregnancy identifies approximately 40% of
those who subsequently will develop preeclampsia.
Compared to individual baseline risk, abnormal uterine
Doppler findings increase the likelihood of preeclampsia
by six times in unselected populations (12).
Screening is only worthwhile if there is an effective
intervention available to prevent the disease or improve
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outcome. In the mid 1980s, small trials suggested that the
prophylactic use of antiplatelet agents could reduce the
incidence of preeclampsia (13,14). However, subsequent
findings of larger trials did not support routine prophylactic
or therapeutic use of aspirin (15-18), and a meta-analysis
of individual data from 31 trials involving 32,000 women of
varying baseline risk concluded that the use of antiplatelet
agents during pregnancy is associated with a modest but
significant reduction of several outcomes including pre-
eclampsia (RR=0.90, 95%CI=0.84-0.97), delivery
before 34 weeks (RR=0.90, 95%CI=0.83-0.98), and
any serious adverse outcome (RR=0.90, 95%CI=0.85-
0.96) (19). The use of aspirin seems to be more effective
in reducing the incidence of preeclampsia in high-risk
women than in those of low to moderate risk. A systematic
review on aspirin to prevent preeclampsia in women at
high risk due to abnormal second-trimester uterine artery
Doppler identified five small randomized trials that
included a total of approximately 500 women receiving
50-100 mg aspirin daily and reported a significant reduc-
tion in the incidence of preeclampsia (OR=0.55,
95%CI=0.32-0.95) (20). However, 2 years later, a large
randomized controlled trial that tested low-dose aspirin in
560 women with abnormal artery Doppler at 23 weeks of
gestation did not confirm those results. According to the
authors, supplementation with 150 mg aspirin did not
significantly decrease the incidence of preeclampsia (18
vs 19%, P=0.6 in the aspirin and placebo groups,
respectively), preterm delivery due to preeclampsia (6
vs 8%, P=0.36) or birth weight below the fifth centile (22
vs 24%, P=0.4) (21). Supplementation with low-dose
aspirin during pregnancy is safe. The incidence of
potential adverse effects associated with aspirin, such
as ante- or post-partum hemorrhage and placental
abruption, were not significantly different in over 32,000
women randomly assigned to receive aspirin versus
placebo (19).
Calcium has also been tested for the prevention of
preeclampsia. A systematic review of 13 randomized trials
that included over 15,000 women concluded that supple-
mentation with 1-2 g calcium carbonate starting in the
second trimester significantly reduced preeclampsia
(RR=0.45, 95%CI=0.31-0.65), and this effect was
greater in high-risk women (five trials, 587 women;
RR=0.22, 95%CI=0.12-0.42), and in those with low
baseline calcium intake (eight trials, 10,678 women;
RR=0.36, 95%CI=0.20-0.65) (22). No side effects of
calcium supplementation were reported in the 13 trials
included in the review.
Despite some controversial findings, the existing
evidence indicates that supplementing high-risk women
with low-dose aspirin and calcium can potentially reduce
their risk of developing preeclampsia. In 2011, the World
Health Organization (23) recognized calcium and aspirin
supplementation during pregnancy as effective interven-
tions to prevent preeclampsia and to reduce maternal
mortality. However, major questions remain unanswered,
such as which specific subgroups of women are more
likely to benefit from this prophylactic medication, what is
the best gestational age to start this preventive treatment,
and what is the ideal dose of the supplements (23,24).
Additionally, to the best of our knowledge, no studies have
analyzed the effects of the combined administration of
these two supplements on the rate of preeclampsia in
high-risk women.
Thus, the main objective of this pilot study was to test
the hypothesis that the administration of a combination of
low-dose aspirin and calcium would reduce the risk of
superimposed preeclampsia in women at high risk for this
condition due to chronic hypertension and abnormal
uterine artery Doppler in the second trimester.
Secondary outcomes of interest in this population were
reduction in the rate of fetal growth restriction and preterm
delivery.
Material and Methods
This randomized, double-blind, placebo-controlled
study took place at the antenatal clinic for hypertensive
disorders of a large, tertiary, university hospital located in
the southern region of the city of Sa˜o Paulo, SP, Brazil.
This clinic offers free antenatal care to low-income
women. Throughout the study period, the same team of
physicians and nurses cared for all the women enrolled in
the study. All participants delivered at the university
hospital and were followed for 6 weeks post-partum.
All women receiving antenatal care and planning to
deliver at the university hospital, and carrying a live,
structurally normal, singleton fetus between 20 and 27
weeks of gestation were eligible if they had chronic
hypertension and an abnormal uterine Doppler exam.
Chronic hypertension was defined as known history of
pre-existing hypertension prior to pregnancy, or blood
pressure readings >140 systolic and/or >90 mmHg
diastolic on two occasions over 6 h apart before week
20 of gestation (2). Gestational age was ascertained by
menstrual dates confirmed by obstetric ultrasound prior to
20 weeks. In case of discrepancies greater than 8 days,
sonographic gestational age was used. Doppler ultra-
sound screening of uterine arteries is routinely performed
at this antenatal clinic in all hypertensive women at 20 to
27 weeks. The first author performed all Doppler exams
using a Diasonics Synergy Color Doppler ultrasonography
unit (OEC Diasonics, USA) with a 3.5-MHz transducer.
Uterine arteries were identified through the transabdom-
inal route using color Doppler. The filter was kept at 50-
100 Hz, the angle of insonation was less than 606 and a
3-mm caliper was placed in the lumen of the vessels.
Women with a high-resistance index (.0.55) and/or a
protodiastolic notch in the placental side or in both uterine
arteries were diagnosed as having abnormal uterine
Doppler (25) and were eligible to enter the study.
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Women were ineligible to participate in the study if they
had increased risk of bleeding due to coagulation
disorders or placenta previa, asthma, allergy to aspirin,
already been diagnosed with preeclampsia before 28
weeks of gestation, or were planning to deliver in other
hospitals.
A single private laboratory (Farma´cia de Manipulac¸a˜o
Amarylis, Brazil) provided all the study medications (pills
containing either 100 mg aspirin or microcrystalline
cellulose and 365-cm transparent plastic envelopes
containing 2 g elemental calcium in the form of calcium
carbonate powder, or cellulose). Placebo pills and powder
were matched to the study supplements for taste, color
and size.
Randomization was carried out using a list of
computer-generated random numbers provided by the
Brazilian Cochrane Centre. Packets containing identical
looking supplements or placebo (pills and envelopes
containing a powder) were placed in individual, consecu-
tively numbered boxes by staff of the Cochrane Centre.
Each box contained either supplements or placebo
following the sequence generated by the randomization
list. Included participants were given the next consecutive
prepacked, numbered box in the order of enrollment. The
study participants and the medical team caring for them
were blinded as to the contents of the boxes.
Upon enrollment, each woman received a box with
140 identical looking oblong white pills (containing either
100 mg aspirin or cellulose) and 140 plastic envelopes
(containing either 2 g calcium or cellulose). They were
asked to keep the box at room temperature away from
direct sunlight and instructed to swallow one pill and
dissolve one envelope of the powder in a glass of water
daily, in the morning, approximately 2 h after breakfast.
All participants were specifically instructed not to take
any aspirin or calcium supplements until delivery. A
prescription for acetominophen was given to all partici-
pants to be taken in case of pain. At each follow-up visit
until delivery, patients were questioned about the use of
any medication since their last visit and the study
instructions were repeated. Women were asked to return
the medication boxes on their first post-partum visit
including the remaining unused pills and envelopes,
which were then counted. Adherence was classified as
poor when the participant had taken less than 50% of the
prescribed daily medication prior to delivery, regular for
those taking 50-69% of the medication, and good for
those taking 70% or more.
The main outcome was superimposed preeclampsia,
defined by a) new-onset proteinuria (.300 mg/24 h) after
the 20th week of pregnancy in a woman with pre-existing
hypertension without proteinuria or b) the sudden
increase in proteinuria, blood pressure, or platelet count
,100,000/mm3, in women with pre-existing hypertension
and proteinuria before 20 weeks of gestation (1).
Secondary outcomes were preterm delivery (before 37
weeks) and fetal growth restriction, defined as birth weight
below the third centile for gender and estimated gesta-
tional age, as described by Yudkin et al. (26). Gestational
age at delivery was estimated as previously described, by
menstrual dates confirmed through sonogram prior to 20
weeks of gestation. The investigators collected data on
outcomes of interest directly from patient charts during
pregnancy and after delivery.
To calculate sample size, the records of all women
with chronic hypertension who received antenatal care in
the clinic in the past 5 years were reviewed and those with
abnormal second-trimester uterine artery Doppler were
selected. The incidence of superimposed preeclampsia in
this group was over 50%. Based on an expected rate of
superimposed preeclampsia of 55% in the participants,
and an estimated reduction of approximately 50% in this
incidence in the group receiving aspirin plus calcium, with
an alpha of 5% and a power of 80%, a total of 22 women
would have to be randomly assigned to each group.
The two-sample test for equality of proportions, the
chi-square test or the Fisher exact test, the independent-
samples t-test, and the Mann-Whitney test were used to
compare the outcomes in the placebo and study groups.
P,0.05 was considered to be significant. All analyses
were conducted according to intention to treat. The Ethics
Committee of Universidade Federal de Sa˜o Paulo
(UNIFESP) approved the study, and all participants gave
written informed consent upon enrollment.
Results
A total of 65 women with chronic hypertension and
abnormal uterine artery Doppler were receiving antenatal
care at the clinic during the study period; 14 did not meet
the selection criteria, 2 refused to participate, and 49 were
randomly assigned – 26 to the placebo group and 23 to
the treatment group. There were no losses of follow-up, all
women continued antenatal care, and were delivered at
the study hospital. Analyses of the main outcome (super-
imposed preeclampsia) were performed on the 23 treated
patients and the 26 women who received placebo
supplements. There were four stillbirths; two in the
placebo group at 20 and 27 weeks (both due to severe
fetal growth restriction), and two in the treated group at 28
and 37 weeks (both due to placental abruption). These
four cases were excluded from the analyses on fetal
growth restriction and preterm delivery but were included
in the preeclampsia analyses (Figure 1). None of the
participants had eclampsia. There were no adverse
events, side effects or complications that could be
attributed to supplementation.
There were no significant differences in the two
groups as to age, parity, race, body mass index, and
blood pressure at randomization (Table 1). Adherence to
prescribed treatment did not differ significantly between
groups; the vast majority of women took over half of the
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prescribed medication (88.4 and 95.6% for the placebo
and treatment groups, respectively).
The rate of superimposed preeclampsia was 28.6%
lower among women receiving aspirin plus calcium than in
the placebo group (52.2 vs 73.1%, respectively), but this
difference did not reach statistical significance
(P=0.112). Women receiving aspirin plus calcium also
had nonsignificant reductions in the rates of low and very
low birth weight infants and slightly heavier infants. There
was an 80.8% reduction in the rate of fetal growth
restriction in the supplemented group (4.8 vs 25%), but
this difference fell short of statistical significance
(P=0.073). One third of the live births in both groups
were delivered before 37 weeks (Table 2).
Discussion
As expected, there was a very high rate of super-
imposed preeclampsia in this selected group of high-risk
women, with over 50% of all participants developing this
complication. This led to a large number of growth-
restricted infants and elective preterm deliveries.
Supplementation with 100 mg aspirin plus 2 g calcium
starting after 20 weeks of pregnancy reduced the rate of
superimposed preeclampsia by 28.6% and the rate of
fetal growth restriction by 80.8% in these women with
Figure 1. Flow diagram of the randomized trial on supplementa-
tion with aspirin plus calcium for preventing superimposed
preeclampsia in high-risk women at 20-27 weeks gestation, in
Sa˜o Paulo, Brazil. Ca: calcium; FGR: fetal growth restriction; PE:
preeclampsia; PTB: preterm birth.
Table 1. Characteristics of 49 women with chronic hypertension and abnormal uterine Doppler enrolled in the randomized trial.
Placebo (n=26) Aspirin + calcium (n=23) P
Age (years)
Mean ± SD 32.3 ± 5.6 31.8 ± 6.2 0.771a
Range 20-41 20-43
Primipara 1 (3.8%) 2 (8.7%) 0.594b
Black race 17 (65.4%) 11 (47.8%) 0.215b
Blood pressure at randomization
Systolic BP (mmHg) 0.416a
Mean ± SD 128 ± 12 126 ± 10
Range 110-158 110-153
Diastolic BP (mmHg) 0.809a
Mean ± SD 84 ± 11 82 ± 11
Range 64-105 70-115
Gestational age at enrollment (weeks)
Mean ± SD 22.2 ± 1.5 22.9 ± 2.0 0.125a
Range 20-27 20-27
Body mass index at randomization (kg/m2)
Mean ± SD 24.6 ± 3.2 24.0 ± 6.0 0.116c
Range 20.6-30.1 16.7-40.4
Adherence to treatment
Poor 3 (11.5%) 1 (4.3%) 0.390b
Regular 7 (26.9%) 11 (47.8%)
Good 16 (61.5%) 11 (47.8%)
Data are reported as number with percent in parentheses, unless otherwise indicated. aIndependent-samples t-test. bChi-square test or
Fisher exact test. cMann-Whitney test.
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chronic hypertension and abnormal second-trimester
uterine artery Doppler. However, these reductions fell
short of statistical difference. The supplements did not
have an effect on the rate of preterm delivery.
We cannot compare our findings to others since this is
the first study to test this combination of supplements in
the prevention of preeclampsia. Although we observed
beneficial effects in the supplemented group, the size of
this effect fell short of our prediction, which was a 50%
reduction in the rate of superimposed preeclampsia. A
possible factor for this smaller effect could be the
relatively late initiation of low-dose aspirin therapy, at a
mean of 22-23 weeks gestation. As previously described,
low-dose aspirin before week 16 is more effective in
preventing preeclampsia (27). However, as in most
developing countries, many high-risk women in our setting
book late for antenatal care. Another possible explanation
for the smaller than expected effect of combined
supplementation could be an interaction between aspirin
and calcium that reduced the bioavailability of each
substance. This hypothesis cannot be confirmed or
refuted because we did not assess the plasma concen-
tration of calcium or aspirin in the participants.
Pharmacological aspects of calcium administration could
also have played a role in the lower than expected effects
of the supplements. The bioavailability of calcium
depends on the type of salt used, the daily dose, and
whether the supplements are ingested with food. Calcium
citrate malate has a higher bioavailability than other forms
and has a good absorption even when consumed on an
empty stomach. However, large doses (.500 mg/day) of
this salt are less well absorbed than lower doses (28).
The etiology and physiopathology of preeclampsia are
not yet completely understood. Preeclampsia is a com-
plex disorder caused by nutritional, environmental and
genetic factors that lead to an inflammatory state,
activation of platelets, imbalance in the production and
activity of thromboxane-prostacyclin and of the free
radicals nitric oxide, superoxide and peroxynitrate by the
vascular endothelium (29). The probable mechanism of
action of low-dose aspirin in the prevention of preeclamp-
sia is by inhibiting the excessive production of thrombox-
ane by platelets in women who are susceptible to this
disorder (13,14,19,20). Low calcium intake may cause
high blood pressure by stimulating the release of
parathyroid hormone or renin, thus leading to increased
intracellular calcium in vascular smooth muscle (30) and
consequent vasoconstriction. A possible mode of action
for calcium supplementation is that it reduces parathyroid
hormone release and intracellular calcium, and so
reduces smooth muscle contractility (22). The explanation
of the potential benefits of offering both aspirin and
calcium to women at high risk for preeclampsia is at
present hypothetical and possibly related to reduction in
inflammatory factors and oxidative stress. A recent trial
involving a small group of Iranian women at risk for
preeclampsia reported that supplementation of low-dose
calcium (500 mg) plus 80 mg aspirin for 9 weeks during
the third trimester of pregnancy resulted in increased
plasma levels of glutathione, total oxidant capacity, and
significantly lower change in high-sensitivity C-reactive
protein in the intervention group (31).
Our study had several strengths, including its origin-
ality, rigorous care to avoid bias in all phases including
selection, randomization, allocation concealment, blinding
of participants and physicians, and reporting of outcomes.
A potential limitation of our study was the lack of
information on the baseline ingestion of dietary calcium in
both groups. However, since the participants were from
the same geographic setting and had similar socio-
economic characteristics, we can infer that the eating
habits of these women were probably very similar.
Table 2. Pregnancy outcomes of 49 women with chronic hypertension and abnormal uterine Doppler at 20-27 weeks gestation
randomly assigned to receive placebo or aspirin plus calcium supplementation during pregnancy.
Placebo (n=26) Aspirin + calcium (n=23) P
Superimposed preeclampsia 19 (73.1%) 12 (52.2%) 0.112a
Preterm deliveryc 8 (33.3%) 7 (33.3%) 0.500a
Fetal growth restrictionc 6 (25.0%) 1 (4.8%) 0.073a
Gestational age at delivery (weeks)
Mean ± SD 37 ± 2.3 36.5 ± 3.5 0.620d
Range 30-39 28-40
Birth weight (g)
Mean ± SD 2563 ± 1033 2604 ± 811 0.879d
Range 540-3980 880-3890
Low birth weight (,2500 g)c 11 (42.3%) 7 (30.4%) 0.390b
Very low birth weight (,1500 g)c 5 (19.2%) 3 (13.0%) 0.706b
Data are reported as number with percent in parentheses, unless otherwise indicated. aTwo-sample test for equality of proportions.
bChi-square test or Fisher exact test. cExcluding stillbirths (2 in placebo and 2 in supplemented group). dIndependent-samples t-test.
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According to the latest national food inquiry survey, the
mean dietary calcium intake of adult Brazilian women is
less than 500 mg/day and over 90% do not reach the
recommended dietary calcium intake for their age (32).
Only a few studies with small sample sizes have
assessed the ingestion of calcium by Brazilian pregnant
women, and they focused on specific subgroups such as
overweight participants and adolescents. According to
those studies, mean daily calcium intake was below the
recommended 1200 mg/day and ranged from 586.6 to
842.9 mg/day in those specific populations of pregnant
women (33-35). The importance of baseline dietary
calcium has been previously demonstrated in large
randomized trials of calcium supplementation for the
prevention of preeclampsia (36,37). In those studies,
women with a high dietary ingestion of calcium
(.1200 mg/day) had no significant reduction in the rate
of preeclampsia, but those with lower dietary calcium
seemed to benefit from supplementation.
Although this study had a relatively small sample size,
all participants were women with essential chronic
hypertension and abnormal uterine Doppler findings,
which is not the case in the majority of published studies.
The sample size calculation was based on an expected
rate of superimposed preeclampsia of 55% in this very
high-risk group of women and an estimated reduction of
50% in the group treated with aspirin plus calcium. There
have been no previous studies to provide guidance on the
expected effects of this combination of drugs. The first
part of this estimation was based on clinical records of
previous patients and it was correct. The incidence of
superimposed preeclampsia was 73.1% in the placebo
group. However, the effect of the supplements was
overestimated. The treated group had an incidence of
superimposed preeclampsia of 52.2%, which corresponds
to a reduction of 28.6%, instead of 50%. Therefore, for
this difference to be statistically significant, it would have
been necessary to include approximately 82 participants
in each group, instead of 22 women. Nevertheless, the
results of this pilot study are valuable for future investiga-
tions on the use of combined supplements for the
prevention of preeclampsia in high-risk women.
This is the first study to assess the effects of the
combined supplementation of calcium plus low-dose
aspirin on the prevention of preeclampsia in women at
high risk for this complication. Our results need to be
confirmed by other studies involving a larger number of
high-risk participants. Besides larger sample sizes, future
studies could test the introduction of combined supple-
mentation at an earlier gestational age (i.e., between 16-
20 weeks), determine the dietary calcium ingestion of the
participants (e.g., through a food questionnaire), and
perform bioavailability studies to ascertain the actual
absorption of aspirin and calcium.
According to the findings of this pilot study, the
combined supplementation of aspirin and calcium starting
at 20-27 weeks of gestation produced a nonsignificant
decrease in the incidence of superimposed preeclampsia
and fetal growth restriction in hypertensive women with
abnormal uterine artery Doppler findings.
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